Latest

2 stories

Hide weekly roundups

Today

Quarterly updateBHB-1893 Braveheart Bio, Inc.

Braveheart Bio posts 52-week oHCM data, pipeline updates with Q3 results

The company reported 52-week extension data for BHB-1893 in obstructive HCM, confirmed Phase 3 and Phase 2b trial timing, and said cash on hand funds operations into 2029.

SEC filing

Friday, November 6

Clinical readoutBHB-1893 Braveheart Bio, Inc.Jiangsu Hengrui Pharmaceuticals

Hengrui and Braveheart report 52-week data on HRS/BHB-1893 in obstructive HCM

At AHA Scientific Sessions 2026, the companies said open-label extension data showed durable LVOT gradient reductions and exercise gains, with most patients remaining on the starting dose.

SEC filing